1. Home
  2. ESPR

ESPR

Esperion Therapeutics Inc.

Logo Esperion Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Founded: 2008 Country:
United States
United States
Employees: N/A City: ANN ARBOR
Market Cap: 396.0M IPO Year: 2013
Target Price: $9.33 AVG Volume (30 days): 6.7M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.03 EPS Growth: N/A
52 Week Low/High: $0.70 - $3.40 Next Earning Date: 05-07-2024
Revenue: $116,334,000 Revenue Growth: 54.14%
Revenue Growth (this year): 132.47% Revenue Growth (next year): 47.48%

Share on Social Networks:

Latest Esperion Therapeutics Inc. News

ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing

All ESPR News